Science and Medicine Group Expands as Commercial Data Insights Leader with Amplion Acquisition

Science and Medicine Group Inc. (SMG), a data intelligence company providing actionable insights about hard-to-reach audiences in life sciences and healthcare, today announced that it has acquired the assets of Amplion Inc., an innovator in AI-powered data intelligence for life science marketing and sales teams seeking to identify business opportunities and accelerate sales growth.

The integration of the Amplion knowledgebase and next-generation data architecture will immediately expand SMG’s capabilities to deliver more comprehensive, actionable insights to commercial organizations at life science equipment and reagent manufacturers as well as pharmaceutical services providers.

“With the Amplion acquisition, Science and Medicine Group is taking decisive action to build the premier data intelligence company serving commercial operations in the life science and healthcare industries. This is the fourth strategic acquisition we have made, and we continue to look for opportunities that expand our unique positioning in the market and accelerate our growth,” said Sam Osman, CEO, Science and Medicine Group.

Amplion’s machine learning-based capabilities enable commercial teams to precisely target the right accounts and most appropriate, and often hard-to-reach, decision makers in pharma, biotech and academia. The Amplion platform and intuitive browser-based user interface provides new levels of hyper-personalized targeting, prospecting, scalability, speed and automation to improve sales and marketing far beyond conventional methods and existing manually searched contact databases. The Amplion knowledgebase analyzes more than 35 million data sources in real-time to generate detailed insights using AI and machine learning on 8 million+ individual contacts across approximately 21,000 organizations globally.

Among the users of the Amplion platform is NanoCellect, a San Diego-based provider of microfluidic flow cytometry technologies who was seeking a better way to find and qualify leads. “We can describe the type of group that we would like to target, but actually finding the right name and contact that is relevant for somebody that would be interested in our product and to initiate that conversation is very challenging,” said Paul DiGregorio, NanoCellect’s VP Commercial. (listen to full interview in this video)

“We’re now setting records in terms of our monthly lead generation activities. We have clearly been able to demonstrate that the investment in the Amplion tool for our inside sales organization has been a positive, successful investment for us and will be part of our long-term strategy,” he added.

“Science and Medicine Group’s customers now have access to a purpose-built, machine learning platform for life science commercial teams, while Amplion’s customers are assured of continued support and long-term investment from a well-established company to further enhance the platform’s capabilities,” said Ed Burnham, who is the Head of Market Research & Analytics and is leading the Amplion business at SMG. “This is another step forward in our growth strategy of integrating existing and new data sources to create new intelligence-enabled products and services and building bridges between all of SMG’s brands to unlock significant value for our customers.”

To read more about Amplion’s capabilities to support sales, marketing and business development in the commercial life sciences industry, go to

About Science and Medicine Group

Science and Medicine Group is on a mission as a premier data intelligence company to deliver actionable insights about hard-to-reach audiences in science and medicine. The company is actively expanding its portfolio of data intelligence solutions, building on the longstanding success of its well-known market research brands, such as Bioinformatics and Kalorama, its media sites, such as and LabPulse, and the Science Advisory Board, a network of scientists immersed in biological research, drug discovery and biopharmaceutical production. The company’s breadth of data-driven offerings and value creation across its world-class brands is powering customer product growth and commercialization efforts to create competitive advantages for its customers. The company is based in Arlington, VA. For more information, visit

Media Contact

Anthony Petrucci


[email protected]


Science and Medicine Group Makes 2021 Predictions for the Lab Instrumentation, Diagnostics and Imaging Industries

The unpredictable events of 2020 might cause one to forswear all prediction-making. Yet for Science and Medicine Group’s publishing brands (Strategic Directions International, BioInformatics, Kalorama Information, IMV, Instrument Business Outlook) are all in the business of prediction-making. Thus once again, we offer our top ten predictions for 2021 based on our market research publications:

  1. Recovery in Academic and Lab Markets: 2020 was obviously an atypical year, and for analytical and life science instrumentation markets (chromatography, spectroscopy, mass spectrometry and other technologies) 2021 will also be atypical as a year of recovery. Academic and government lab budgets are expected to take more than one year to recover, since public funding has been so impacted by lower tax revenues and new spending priorities to directly address the COVID-19 crisis. This is from Strategic Directions International (SDI), authors of the The 2020 Global Assessment Report: The Laboratory Analytical & Life Science Instrumentation Industry, which offers market forecasts for over 80 scientific tool segments.
  2. Growth Will Be Weighted Toward Asia: The current resurgence of the pandemic in the US and Europe will delay the recovery of these markets in 2021. But many Asia Pacific countries that were more successful in suppressing the disease are already seeing increased demand for lab instrumentation and equipment.
  3. M&A Wil Accelerate for Instrument Companies: Instrument Business Outlook (IBO), the premier newsletter for instrument executives, expects M&A activity to increase in 2021. Although the COVID-19 outbreak may have slowed M&A activity earlier this year, that changed late in the year. The largest deals in the cell-based instrument market in 2020 came from 10x Genomics and Bio-Rad Laboratories and were focused on single-cell analysis. 10x Genomics purchased two companies in the spatial analysis space, including its $350 million acquisition of ReadCoor, while Bio-Rad completed a $100 million deal for Celsee.
  4. Radiation Therapy Capital Purchases to Rise: Although the COVID-19 pandemic has impacted 2020’s capital budgets for radiation therapy (RT) equipment, it is likely that investments are being shifted to 2021–2022. This is according to IMV’s RT Market Outlook. Going forward, higher than 25% of sites [25% of sites or 25% referring to some aspect of budget?] are planning capital budgets of $1 million or more in 2021 and 2022, compared to the 18%’ sites’ 2020 budgets.
  5. Urgent Care Provides a Perfect Outlet for COVID-19 Vaccines: Urgent care locations have grown over the past decade. Kalorama Information estimates the number of urgent care locations in the United States to be 9,900, growing from nearly 7,000 in 2013. The spectacular growth is driven by a need for more healthcare services, an increase in insured populations and resistance to physician office waiting times. Now, there is a new opportunity with new COVID-19 vaccines. “There is no better front-line for distribution of a widely utilized vaccine among a healthy population,” says Bruce Carlson, Publisher of Kalorama Information. “Of course, this will be supplemented by traditional vaccine outlets such as governments and physician offices. But urgent care offers walk-in, no previous-relationship service, which is ideal for a vaccine.” According to the market research firm’s report The U.S. Urgent Care Center Market,what distinguishes urgent care centers is that they are walk-in clinics offering extended-hour access for acute illness and injury care. Such care is either beyond the scope or availability of the typical primary care practice and offers more focused care than an emergency room would.
  6. Customized Retargeted Ads Will Help Instrument Companies Advertise Their Products: If they use it correctly, that is. According to The 2020 Best Practices for Advertising to Life Scientists: Online and in Print,a report conducted by BioInformatics, companies should pay attention to age and demographic preferences, and keep ads simple and benefit-messages concise. Audiences also will respond to retargeted ads, if they are done well. There is also generational differences in how audiences respond to ads. This is one of the many insights in the report, which essentially asked life scientists how they prefer to learn about new products.
  7. Antibody testing for COVID-19 Will Increase: This will be brought about by vaccine effectiveness, and address both the official studies of vaccine effectiveness and the informal checking by concerned individuals. Antibody testing was talked about last year in the midst of one of the heaviest periods of the COVID-19 crisis as a test used to “return to work.” That did not work out in terms of promoting [?] a great number of tests, but expect a resurgence.
  8. Applied Markets for Lab Instrumentation Will Grow: Labs doing applied testing, such as food and environmental analyses, are forecast to increase lab tool spending by 7%–8% in 2021 on average.
  9. New Instrument Entrants in Diagnostics Will “Stay In:” Expect more diagnostics investments by instrument companies as their COVID-19 solutions opened the door to clinical labs and partners they may not have worked with before. Bruker, PerkinElmer and Fluidigm are among the lab tool makers expanding their diagnostics businesses. QIAGEN recently announced that a huge increase in instrument placements in 2020 for COVID 19-testing will pay dividends for consumables sales in years to come.
  10. High-Sensitivity Troponin Point-of-CareTest Is Approval: Troponin can be a predictor of heart attacks and a marker of coronary disease status. hsTn assays are able to accurately measure 10-fold lower concentrations of cardiac troponin than contemporary assays. The use of high-sensitivity troponin in point-of-care (POC) settings, particularly emergency rooms, has shown promise. Although they have been used with COVID-19 patients to detect severity, there are no FDA approvals. A product from Quidel has gained CE Marking, and Abbott i-Stat’s test has shown high-sensitivity levels, though there is no predicting which brand or test will be the first POC hsTN.

What about last year’s predictions?

COVID-19 certainly threw last year’s predictions for a loop; for example, those about Asian markets in general, imaging volumes in the U.S., and multiphotonics and sequencing prep sales. Now, we extend those predictions to 2021. Others held, more or less, to be true: CAR-T therapy sales should near a billion dollars with final results still out; AI remains most useful in imaging applications; mass spectrometry is being brought to bear in COVID-19 detection; and hematology handhelds, while limited by COVID-19, continue to grow within the category of hematology tests.

Science and Medicine Group Again Named to Inc. Magazine’s List of America’s Fastest-Growing Private Companies

ARLINGTON, Va.Aug. 13, 2020 / — Inc. magazine today revealed that Science and Medicine Group was again named to its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment—its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“Science and Medicine Group has continued to flourish despite the challenges of the novel coronavirus and the resulting economic slowdown,” said Craig Overpeck, Chief Executive Officer. “Our life science, diagnostic and medical imaging customers are on the frontlines of the fight against COVID-19 and we’re supporting them by making key data available so they can monitor laboratory and imaging facility status and focus their resources on where they are needed most. Our customer-centric approach by our entire staff and shared passion with our customers is driving our growth.”

Not only have the companies on the 2020 Inc. 5000 been very competitive within their markets, but the list as a whole shows staggering growth compared with prior lists as well. The 2020 Inc. 5000 achieved an incredible three-year average growth of over 500 percent, and a median rate of 165 percent. The Inc. 5000’s aggregate revenue was $209 billion in 2019, accounting for over 1 million jobs over the past three years.

Science and Medicine Group, headquartered in Arlington, Virginia, is an integrated business information and media firm serving clients in the life science, diagnostic, medical imaging and dental industries. Business information products and services include hundreds of market reports, databases of installed diagnostic and imaging instruments, a widely-read executive newsletter, and a custom research and data analysis team to help clients grow their business. Science and Medicine Group moved up 7 spots to be ranked 17th among Media Companies due to its highly targeted, digital audiences comprised of scientists, radiologists, clinical lab professionals, and dentists.

“The companies on this year’s Inc. 5000 come from nearly every realm of business,” says Inc. editor-in-chief Scott Omelianuk. “From health and software to media and hospitality, the 2020 list proves that no matter the sector, incredible growth is based on the foundations of tenacity and opportunism.”

About Science and Medicine Group

Science and Medicine Group is a leading business information and media firm serving the life science, analytical instrument, clinical diagnostic, diagnostic imaging, and dental industries. The company’s portfolio includes market intelligence brands BioInformatics, IMV Medical Information, Instrument Business Outlook, Kalorama Information, and Strategic Directions International and media brands,,, and

About the Inc. 5000

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. For more information, visit


The 2020 Inc. 5000 is ranked according to percentage revenue growth when comparing 2016 and 2019. To qualify, companies must have been founded and generating revenue by March 31, 2016. They had to be U.S.-based, privately held, for profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2019. Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at

BioInformatics Launches New Experts-on-Demand Qualitative Research Service

BioInformatics, part of Science and Medicine Group, today announced the launch of a new qualitative research solution: Experts-on-Demand. The service helps connect companies with a network of thousands of life science and medical experts for one-hour telephone consultations.

 “The pace of science, technology, and medicine is moving faster than ever, and we have built a qualitative offering to match the new speed of business today. Our Experts-on-Demand consultants are profiled and responsive to meet the increasing needs of our clients,” said Craig Overpeck, chief executive officer of Science and Medicine Group.

The experts are drawn from The Science Advisory Board®, an expert network formed in 1997. Tens of thousands of laboratory professionals representing basic and translational life science research, drug discovery, and clinical diagnostics routinely participate in BioInformatics’ quantitative and qualitative global market research projects. The proprietary global network encompasses more than 25 market segments and includes scientists and clinicians with profiled expertise in 80 different research and diagnostic techniques.

“Experts-on-Demand facilitates direct communication between those on the cutting edge of science and medicine with those companies who must support them with ever more innovative technologies,” said Overpeck.

More information on Experts-on-Demand can be found here.

BioInformatics, now part of Science and Medicine Group, is the premier research and advisory firm serving the life science, clinical diagnostics, and analytical instrument industries. By leveraging our expert network of more than 50,000 profiled life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

Science and Medicine Group Named to 2019 Inc. 5000 List

“Being named to the Inc. 5000 list is a tremendous achievement and a testament to the hard work of our talented staff,” said Craig Overpeck, CEO of Science and Medicine Group. “Our growth reflects the accelerated pace at which our clients are pursuing the use of science and medicine together to make our world a better place. We are proud to help them bring new tests, technologies, and treatments to the market utilizing our insights and global audiences of scientists and clinicians.”

Not only have the companies on the 2019 Inc. 5000 (see list at been very competitive within their markets, but the list as a whole shows staggering growth compared with prior lists. The 2019 Inc. 5000 achieved an astounding three-year average growth of 454%, and a median rate of 157%. The Inc. 5000’s aggregate revenue was $237.7 billion in 2018, accounting for 1.2 million jobs over the past three years.

“The companies on this year’s Inc. 5000 have followed so many different paths to success,” says Inc. Editor-in-Chief James Ledbetter. “There’s no single course you can follow or investment you can take that will guarantee this kind of spectacular growth, but what they have in common is persistence and seizing opportunities.”

Science and Medicine Group is a leading business information and media firm serving the life science, analytical instrument, clinical diagnostic, diagnostic imaging, and dental industries. The company’s portfolio includes market intelligence brands BioInformatics, IMV Medical Information, Instrument Business Outlook, Kalorama Information, and Strategic Directions International and media brands,,, and Science and Medicine Group, ranked No. 23 among media companies in the Inc. 5000, helps clients create strategies and products to win markets and provides platforms to digitally engage their markets through a variety of innovative solutions.

Media contact:

Justin Dudash
Vice President, Marketing
Science and Medicine Group Inc.
671 North Glebe Rd Suite 1610
Arlington, VA 22203
[email protected]

Science and Medicine Group Releases Two New Products for AACC 2019

Science and Medicine Group launches two new products at the annual meeting of the American Association for Clinical Chemistry (AACC) to help manufacturers of diagnostic instruments connect with their customers at clinical laboratories. The company will be demonstrating its new healthcare vertical portal,, which adds to the growing number of media properties in the Science and Medicine Group portfolio. It will also debut a new clinical instrument database for IVD vendors from Kalorama.

The first is, a website designed to provide late-breaking news and information to professionals working in clinical laboratories. Laboratory medicine is a rapidly growing field that is experiencing a technology transformation as new tools are becoming available to clinicians, such as digital pathology, liquid biopsy, point-of-care testing, mass spectrometry, and next-generation sequencing, as well as improved laboratory information systems (LIS) and IT support software. In addition, specialized content areas, called Communities, enable members to stay on top of important industry segments.  Segments include in vitro diagnostics, pathology, microbiology, point-of-care testing, and genomics. Advertising and sponsorship opportunities are now available.  The website is available at and the media kit can be downloaded here:

The second product launched is the Kalorama Clinical Masterfile. The product is designed to help clinical diagnostic vendors find customers, verify the data their sales team is providing, and locate weak points in the competition. The Clinical Masterfile is the most comprehensive database of the installed base of clinical laboratory equipment in the U.S.  An ongoing survey of more than 5,300 facilities continuously updates data on more than 41,000 analyzers including manufacturer, model, number installed, year installed and department location. The information is continuously gathered by phone and online reporting system with pathologists and lab managers at US CLIA labs.  Every major modality is covered including chemistry, coagulation, hematology, immunoassay, integrated systems, microbiology, and molecular diagnostics. Key demographics such as address, population served, budget and points-of-contact are included. More information is available at:

“The release of these new products further enhance our ability to connect our diagnostic clients with their customers at clinical laboratories,” said Craig Overpeck, CEO of Science and Medicine Group. “We facilitate the exchange of valuable information between the buyers and sellers in this fast changing market to the mutual benefit of both.”

Representatives will be on site to discuss both products at booth 4326 at the American Association for Clinical Chemistry Meeting in Anaheim, CA, August 6th to August 8th, 2019.

About Science and Medicine Group
Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Our clients, including some of the top Fortune 500 companies in the world, use our business intelligence, market research and publications, and marketing platforms to grow their businesses globally.

Media Contact:

Jonathan West
Science and Medicine Group
671 North Glebe Rd Suite 1610
Arlington, VA 22203
[email protected]

BioInformatics Inc. Acquires Kalorama Information

ARLINGTON, VA – BioInformatics Inc., the premier research and advisory company serving the life science industry, today announced the acquisition of Kalorama Information from

For more than 20 years, Kalorama Information, a division of, has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, healthcare, medical devices, and pharmaceuticals.

“The Kalorama name has become the marquee brand in the Life Sciences and Diagnostics space and we couldn’t be more proud of it,” said Rob Granader, CEO and founder of and its publishing division. “I named the brand 20 years ago after the area where I was living at the time, and it has served the marketplace well.”   Kalorama is a Greek word meaning beautiful vista and is a neighborhood in the Northwest quadrant of Washington, DC.

“Kalorama Information is a premier source of high-quality market research reports for corporate decision makers in the clinical diagnostics and life science space,” says Craig Overpeck, CEO of BioInformatics. “This acquisition further solidifies our leadership position in the life science, diagnostics, and imaging markets while presenting us with exciting opportunities in adjacent healthcare markets including medical device, pharma, and biotech.”

Under the terms of the deal, will continue selling Kalorama’s reports for BioInformatics including subscription Knowledge Centers, through Profound, and academic bundles.

“The convergence of science and medicine is ushering in the era of personalized medicine and our clients are expanding into new areas,” commented Overpeck, “Our latest acquisition shows our determination to be at the center of this transformation with both actionable market intelligence and innovative marketing opportunities for life science companies.”

BioInformatics Inc. acquires IMV Publishing and creates the Science and Medicine Group

ARLINGTON, VA – BioInformatics Inc., the leading market research firm supporting the analytical instrumentation and life science industries, and owner of The Science Advisory Board®, is pleased to announce the acquisition of IMV Publishing. This latest acquisition by BioInformatics Inc. creates an integrated business information and media group delivering high-value content to the market’s buyers and sellers using a broad range of media formats. The companies share deep expertise in the areas of producing market intelligence, generating premium content, profiling customers and delivering targeted marketing to large, curated online communities of scientific and medical professionals.

Founded in 1977, IMV is a recognized leader in market research and online publishing for the medical imaging and clinical diagnostic instruments markets. With offices in Chicago, Tucson, and San Francisco, IMV offers a broad range of market research products and reports and media properties including Aunt Minnie the leader in online medical imaging news and radiology CME and DrBicuspid the fastest growing dental news and CE digital property.

The assets of IMV will be combined with existing capabilities including BioInfo Market Research, The Science Advisory Board ® , Strategic Directions International (SDI) creator of the SDi Global Report, and Instrument Business Outlook  a bi-weekly publication subscribed to and read by senior executives in the analytical instrument market.

Together all companies and assets will be managed and integrated under the newly created Science and Medicine Group  which will be headquartered in Arlington Virginia and have services in business intelligence / market research, digital media and marketing, publishing, and job boards for scientists, lab managers, dentists, and radiologists.

Brands of Science & Medicine Group
The premier online destination  for radiologists seeking news, advice and professional resources.

BioInformatics Inc.
Leading market research & media for the life science industry.
A member-driven website dedicated to dentists, specialists, and other dental professionals.

Leading publisher of market research reports for the clinical diagnostics & radiology markets.

Instrument Business Outlook
Bi-weekly executive newsletter in-depth analysis of market developments, new product introductions and financial performance.

Strategic Directions International (SDi)
The most trusted and respected market research firm serving the analytical instrument market.

The Science Advisory Board
The world’s largest market research panel of life scientists and laboratory professionals.

“Over the next 5 to 10 years we see a world where instruments and diagnostics – including analytical, imaging, and clinical – will converge to lead a precision medicine revolution,” said Craig Overpeck, CEO of Science and Medicine Group, “We are putting a stake at the intersection of science, medicine, and technology to help guide companies with transformative information and media products and services for converging markets that will make a difference in the lives of billions of people for the next century.” With the combined entities, Science and Medicine Group will become one of the top 50 full service market research companies in the world by exclusively focusing on helping science and medicine businesses grow.

Broad Oak Capital Partners (Bethesda, MD) provided financing to facilitate the transaction.

About Science and Medicine Group

Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Our clients, including some of the top Fortune 500 companies in the world, use our business intelligence, market research and publications, and marketing platforms to grow their businesses globally.

Media Contact:
Monika Mahajani
BioInformatics Inc., part of Science and Medicine Group
671 North Glebe Rd Suite 1610
Arlington, VA 22203
703-778-3080 x-37
[email protected]